Deutetrabenazine
Brand names: Austedo, Austedo Xr · Active ingredient: Deutetrabenazine
In short: AUSTEDO XR® and AUSTEDO® are indicated in adults for the treatment of: chorea associated with Huntington’s disease tardive dyskinesia
What is Deutetrabenazine used for?
AUSTEDO XR® and AUSTEDO® are indicated in adults for the treatment of:
chorea associated with Huntington’s disease
tardive dyskinesia
⚠ Boxed warning (FDA's strongest warning)
AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of AUSTEDO XR or AUSTEDO must balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician.
Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression
.
Deutetrabenazine dosage
The dose of AUSTEDO XR and AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. Table 1 displays the recommended dosage and important administration instructions of AUSTEDO XR and AUSTEDO when first prescribed to patients who are not being switched from tetrabenazine (a related VMAT2 inhibitor).
Table 1: Recommended Dosage and Important Administration Instructions for AUSTEDO XR and AUSTEDO
AUSTEDO XR
extended-release tablet | AUSTEDO
tablet
Recommended Starting Dosage | 12 mg once daily
(12 mg per day) | 6 mg twice daily
(12 mg per day)
Recommended Dose Titration | The dosage of AUSTEDO XR or AUSTEDO may be increased at weekly intervals in increments of 6 mg per day based on reduction of chorea or tardive dyskinesia, and tolerability, up to a maximum recommended daily dosage of 48 mg .
Important Administration Instructions | Administer AUSTEDO XR with or without food .
Swallow AUSTEDO XR whole. Do not chew, crush, or break tablets.
Administer AUSTEDO XR once daily. | Administer AUSTEDO with food .
Swallow AUSTEDO whole. Do not chew, crush, or break tablets.
Administer AUSTEDO total daily dosages of 12 mg or above in two divided doses.
Switching Between AUSTEDO and AUSTEDO XR | When switching between AUSTEDO tablets (twice daily) and AUSTEDO XR extended-release tablets (once daily), switch to the same total daily dosage.
Discontinue tetrabenazine and initiate AUSTEDO XR or AUSTEDO the following day. The recommended initial dosing regimen of AUSTEDO XR or AUSTEDO in patients switching from tetrabenazine to AUSTEDO XR or AUSTEDO is shown in Table 2.
Table 2: Recommended Initial Dosing Regimen when Switching from Tetrabenazine to AUSTEDO XR or AUSTEDO
Current tetrabenazine
daily dosage | Initial regimen of AUSTEDO XR extended-release tablet | Initial regimen of
AUSTEDO tablet
12.5 mg | 6 mg once daily | 6 mg once daily
25 mg | 12 mg once daily | 6 mg twice daily
37.5 mg | 18 mg once daily | 9 mg twice daily
50 mg | 24 mg once daily | 12 mg twice daily
62.5 mg | 30 mg once daily | 15 mg twice daily
75 mg | 36 mg once daily | 18 mg twice daily
87.5 mg | 42 mg once daily | 21 mg twice daily
100 mg | 48 mg once daily | 24 mg twice daily
After patients are switched to AUSTEDO XR or AUSTEDO, the dose may be adjusted at weekly intervals .
In patients receiving strong CYP2D6 inhibitors, the total daily dosage of AUSTEDO XR or AUSTEDO should not exceed 36 mg .
In patients who are poor CYP2D6 metabolizers, the total daily dosage of AUSTEDO XR or AUSTEDO should not exceed 36 mg .
Treatment with AUSTEDO XR or AUSTEDO can be discontinued without tapering. Following treatment interruption of greater than one week, AUSTEDO XR or AUSTEDO therapy should be re-titrated when resumed. …
How to take Deutetrabenazine — instructions & advice from the label
Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide).
Administration Instructions
Instruct patients to swallow AUSTEDO XR or AUSTEDO whole and not to chew, crush, or break AUSTEDO XR or AUSTEDO .
AUSTEDO XR
Advise patients to take AUSTEDO XR with or without food in once-daily doses. Inform patients not to be concerned if they occasionally notice something that looks like a tablet shell in their stool .
AUSTEDO
Advise patients to take AUSTEDO with food. Advise patients to take daily dosages of 12 mg or higher in two divided doses (twice daily).
Risk of Depression and Suicide in Patients with Huntington’s Disease
Advise patients, their caregivers, and families that AUSTEDO XR and AUSTEDO may increase the risk of depression, worsening depression, and suicidality, and to immediately report any symptoms to a healthcare provider .
Prolongation of the QTc Interval
Inform patients to consult their physician immediately if they feel faint, lose consciousness, or have heart palpitations . Advise patients to inform physicians that they are taking AUSTEDO XR or AUSTEDO before any new drug is taken. …
Warnings & precautions
Do not take this medicine if: AUSTEDO XR and AUSTEDO are contraindicated in patients:
With Huntington’s disease who are suicidal, or have untreated or inadequately treated depression .
With hepatic impairment .
Taking reserpine. At least 20 days should elapse after stopping reserpine before starting AUSTEDO XR or AUSTEDO .
Taking monoamine oxidase inhibitors (MAOIs). AUSTEDO XR and AUSTEDO should not be used in combination with an MAOI, or within 14 days of discontinuing therapy with an MAOI .
Taking tetrabenazine or valbenazine .
Patients with Huntington’s disease are at increased risk for depression, and suicidal ideation or behaviors (suicidality). AUSTEDO XR and AUSTEDO may increase the risk for suicidality in patients with Huntington’s disease.
In a 12-week, double-blind, placebo-controlled trial, suicidal ideation was reported by 2% of patients treated with AUSTEDO, compared to no patients on placebo; no suicide attempts and no completed suicides were reported. Depression was reported by 4% of patients treated with AUSTEDO.
When considering the use of AUSTEDO XR or AUSTEDO, the risk of suicidality should be balanced against the need for treatment of chorea. All patients treated with AUSTEDO XR or AUSTEDO should be observed for new or worsening depression or suicidality. If depression or suicidality does not resolve, consider discontinuing treatment with AUSTEDO XR or AUSTEDO.
Patients, their caregivers, and families should be informed of the risks of depression, worsening depression, and suicidality associated with AUSTEDO XR and AUSTEDO, and should be instructed to report behaviors of concern promptly to the treating physician. Patients with Huntington’s disease who express suicidal ideation should be evaluated immediately. …
Deutetrabenazine side effects
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
Depression and Suicidality in Patients with Huntington’s disease
QTc Prolongation
Neuroleptic Malignant Syndrome (NMS)
Akathisia, Agitation, and Restlessness
Parkinsonism
Sedation and Somnolence
Hyperprolactinemia
Binding to Melanin-Containing Tissues
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The studies described below were conducted with AUSTEDO tablets; adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets.
Patients with Huntington’s Disease
Study 1 was a randomized, 12-week, placebo-controlled study in patients with chorea associated with Huntington’s disease. A total of 45 patients received AUSTEDO, and 45 patients received placebo. Patients ranged in age between 23 and 74 years (mean 54 years); 56% were male, and 92% were Caucasian. The most common adverse reactions occurring in greater than 8% of AUSTEDO-treated patients were somnolence, diarrhea, dry mouth, and fatigue. Adverse reactions occurring in 4% or more of patients treated with AUSTEDO, and with a greater incidence than in patients on placebo, are summarized in Table 3. …
Drug interactions
A reduction in AUSTEDO XR or AUSTEDO dose may be necessary when adding a strong CYP2D6 inhibitor in patients maintained on a stable dose of AUSTEDO XR or AUSTEDO. Concomitant use of strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine, bupropion) has been shown to increase the systemic exposure to the active dihydro-metabolites of deutetrabenazine by approximately 3-fold. The daily dose of AUSTEDO XR or AUSTEDO should not exceed 36 mg per day in patients taking strong CYP2D6 inhibitors .
Reserpine binds irreversibly to VMAT2 and the duration of its effect is several days. Prescribers should wait for chorea or dyskinesia to reemerge before administering AUSTEDO XR or AUSTEDO to help reduce the risk of overdosage and major depletion of serotonin and norepinephrine in the central nervous system. At least 20 days should elapse after stopping reserpine before starting AUSTEDO XR or AUSTEDO. AUSTEDO XR and AUSTEDO should not be used concomitantly with reserpine .
AUSTEDO XR and AUSTEDO are contraindicated in patients taking MAOIs. AUSTEDO XR and AUSTEDO should not be used in combination with an MAOI, or within 14 days of discontinuing therapy with an MAOI . …
About this medicine
AUSTEDO XR extended-release tablets and AUSTEDO tablets are formulated with deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor for oral administration. The molecular weight of deutetrabenazine is 323.46; the pKa is 6.31. Deutetrabenazine is a hexahydro-dimethoxybenzoquinolizine derivative and has the following chemical name: (RR, SS)-1, 3, 4, 6, 7, 11b-hexahydro-9, 10-di(methoxy-d3)-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one.
The molecular formula for deutetrabenazine is C19H21D6NO3. Deutetrabenazine is a racemic mixture containing the following structures:
Deutetrabenazine is a white to slightly yellow crystalline powder that is sparingly soluble in water and soluble in ethanol. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7ea3c60a-45c7-44cc-afc2-d87fa53993c0. Read the full official label on DailyMed.